APOTEA.ST(APOTEA.ST)
APOTEA.ST
No analyst ratings available
No analyst price targets available for APOTEA.ST
Analyst coverage may not be available for this symbol
No recent analyst actions
| Metric | FY2026E | FY2027E | FY2028E |
|---|---|---|---|
| Revenue Avg | $8.07B | $9.12B | $10.14B |
| Low | $8.01B | $8.87B | $10.13B |
| High | $8.14B | $9.37B | $10.14B |
| EBITDA Avg | $361M | $408M | $453M |
| Low | $358M | $397M | $453M |
| High | $364M | $419M | $454M |
| EBIT Avg | $227M | $256M | $285M |
| Low | $225M | $249M | $284M |
| High | $229M | $263M | $285M |
| Net Income Avg | $283M | $358M | $419M |
| Low | $278M | $351M | $416M |
| High | $287M | $365M | $423M |
| EPS Avg | $2.71 | $3.44 | $4.03 |
| Low | $2.67 | $3.37 | $3.99 |
| High | $2.76 | $3.50 | $4.06 |
| Analysts (Rev / EPS) | 2 / 2 | 2 / 2 | 2 / 2 |
| Metric | Q3 2026 | Q4 2026 |
|---|---|---|
| Revenue Avg | $1.99B | $2.12B |
| Low | $1.99B | $2.12B |
| High | $1.99B | $2.12B |
| EBITDA Avg | $89M | $95M |
| Low | $89M | $95M |
| High | $89M | $95M |
| EBIT Avg | $56M | $60M |
| Low | $56M | $60M |
| High | $56M | $60M |
| Net Income Avg | $74M | $57M |
| Low | $72M | $57M |
| High | $75M | $57M |
| EPS Avg | $0.71 | $0.54 |
| Low | $0.69 | $0.54 |
| High | $0.72 | $0.54 |
| Analysts (Rev / EPS) | 1 / 2 | 1 / 1 |